China Tracker - Details for ShangPharma (SHP)

 ShangPharma
Shares Outstanding (MRQ): 18.64 mill
New Shares / Dilution (TTM): 7.08 mill61.18%
Cash (MRQ): 49.16 mill0.00%
Account Receivables (MRQ): 16.91 mill0.00%
Account Receivables (Q/Q): + 0.89 mill5.58% 
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): 10.78% 
Revenue Growth (Y/Y): 29.36% 
Net Income Growth (Q/Q): 53.03% 
Net Income Growth (Y/Y): 126.18%
EPS Growth (Y/Y): 40.32%
Net Margin (Q/Q): 23.0% (16.7%)6.40% 
Net Margin (Y/Y): 23.0% (13.2%)9.90% 
EPS | P/E (2 MRQ Projection): $1.050.00 
CFPS | P/CF (2 MRQ Projection): $1.000.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: PricewaterhouseCoopers
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2012-10-21): $0.940.00 
 Basic Facts and History (show more)
Reporting Type: Foreign Company (20-F Filings) 
Going Public: IPO on 2010-10-19 
IPO Price: $15.00 (-100.00% since IPO)

 Business Outlook

We will focus on managing our costs in the second half of the year, and are confident that we will meet our financial guidance for 2011. The Company expects net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010. Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010. Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

(Source: PR Newswire, 2011-08-22)

The Company reconfirms its guidance for full year 2011. The Company expects net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010. Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010. Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

(Source: PR Newswire, 2011-05-19)

For the full year 2011 the Company expects net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010. Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010. Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

(Source: PR Newswire, 2011-03-15)

    see all Business Outlook notes


Warning: Division by zero in /home/fixyou/public_html/tracker_details.php on line 652
 Analyst Coverage (show more)
2011-08-22CitigroupReiterationBuy$16.00
2011-08-16J.P. MorganReiterationOverweight$16.00
2011-08-09William BlairReiterationOutperformn/a
2011-06-16William BlairReiterationOutperformn/a
2011-05-20OppenheimerReiterationOutperform$17.00

SHP is currently followed by 5 analysts. All 5 give the stock a positive rating. The average price target is 16.33.


    see all Analyst Ratings
SHP
Healthcare & Drugs
SCORE
6
READ: Score Cards Explained
SAFETY/RISK SCORE
MODERATE SAFETY
DETAILS: Safety/Risk Model for SHP
Current Price:  n/a
F10k Day (2010-10-19): -100.00%$12.75
2010 Close: -100.00%$11.50
2011 Close: -100.00%$7.27
High (2012-04-26): -100.00%$8.59
Low (2012-06-14): -100.00%$5.81
Exchange:
Market Capitalization: n/a
Total Shares: 18.64 mill
Float: n/a
Avg Volume: 15.30 k
Short Interest: 9.60 k
Short Ratio: 1.13%0.6 d
Last Quarter: 2010-12-31
Revenue (MRQ): 25.61 mill
Net Income (MRQ): 5.90 mill
Op. Cash Flow (MRQ): 4.66 mill
all financial data provided without warranty